Postoperative Pain Clinical Trial
Official title:
Efficacy of Liposomal Bupivacaine for Pain Control After Percutaneous Nephrostolithotomy
Percutaneous nephrostolithotomy (PCNL) is a common endoscopic procedure performed for upper
urinary tract calculus disease. Despite being minimally invasive, it is associated with
significant postoperative pain, often necessitating inpatient hospitalization and narcotic
pain medications. Additionally, one of a number of catheters is often left protruding from
the access tract for a period of time following the procedure, adding to patient discomfort.
Attempts have been made to study peri-tubular or access tract analgesic installation, which
have shown promise.1-2 However, no studies, to our knowledge, have examined the use of
liposomal bupivacaine preparations in this regard. In this study we hope to prospectively
analyze the use of liposomal bupivacaine injected to the access tract site at the time of
PCNL and determine its effects on postoperative narcotic requirement and pain scores.
Patients presenting for PCNL will be randomized to either the liposomal bupivacaine or usual
care, which involves no injection of local anesthesia. Patients will then be followed during
their inpatient stay. Total narcotic requirement (in milligrams) and pain scores (using
Wong-Baker FACES rating scale) will be compared.3 Typical postoperative care and discharge
criteria will not change during the course of this study.
Subjects will be randomly assigned by a 1:1:1 ratio to one of the following groups:
1. Saline (control arm)
2. Liposomal bupivicaine (long-acting local anesthetic)
3. Bupivacaine (local anesthetic)
The Biostatistics Unit will develop a randomization procedure using a permuted block
design. Randomization will be stratified by site (LIJ or NSUH). The randomization
process will occur in REDCap using the Randomization Module. Details of the procedure,
including required record keeping, will be further developed upon approval of this
protocol.
Patients undergoing PCNL will need no alterations of procedure in regards to
positioning, obtaining access, or removal of calculi. Efforts will be made to remove the
calculus with use of one access tract only; however, if the surgeon performing the
procedures deems that additional access tracts are needed they can be obtained.
Similarly, efforts will be taken to include a single nephrostomy tube without the need
for a ureteral stent. However, if the attending surgeon deems either of these factors
need to be altered, he may do so at his discretion. The use of multiple access tracts,
multiple nephrostomy tubes, or a ureteral stent will then disqualify the patient from
the trial and they shall then be withdrawn from the study. Because of the nature of the
procedure, it is difficult to predict with certainty if patients will need any of these
alterations and thus these decisions may need to be made intraoperatively.
If the patient still meets inclusion criteria, 20 mL of agent will be infiltrated
subcutaneously depending on what arm the patient was randomized to. 10 mL will be place
at the lateral edge of the tract while 10 mL will be placed at the medial edge. The
patient will be awakened without any other changes to standard PCNL protocol. All PCNL
procedures will be performed in the aforementioned manner by one of three fellowship
trained endourologists with high-volume stone practices (David Hoenig, Zeph Okeke, and
Arthur Smith).
The primary outcome being assessed is the patient's pain rating at 24 hours after the
procedure. All patient scores will be recorded using a specific VAS, the Wong-Baker
FACES Pain Rating Scale. These values will be converted to a numerical scale from 0-10
accordingly. Patients will be assigned a pain rating handout which will be present in
their hospital room for 48 hours or until they are discharged, whichever comes first.
Nursing staff or a urology inpatient team member will prompt the patient at the 24 hour
period to describe their pain using the FACES scale and they will record this on their
handout. Nursing or a urology inpatient team member will collect handouts at time of
discharge or after 48 hours, whichever comes first.
Primary Objective:
To determine the effects of liposomal bupivacaine injections at the access site during
PCNL on postoperative pain and narcotic requirement.
Primary Outcome:
• Visual analog scale (VAS) at 24 hours (Liposomal bupivicaine vs. bupivicaine only)
Secondary Outcomes:
- Total dose of narcotics (mg) over the course of hospital stay
- VAS pain scores (across time)
- Length of Stay (LOS)
- Time-to-first rescue pain medication after surgery
Randomization:
Subjects will be randomly assigned by a 1:1:1 ratio to one of the following groups:
4. Saline (control arm)
5. Liposomal bupivicaine (long-acting)
6. Bupivacaine (local anesthetic)
The Biostatistics Unit will develop a randomization procedure using a permuted block design.
Randomization will be stratified by site (LIJ or NSUH). The randomization process will occur
in REDCap using the Randomization Module. Details of the procedure, including required record
keeping, will be further developed upon approval of this protocol.
Statistical Methods:
Descriptive statistics (means ± standard deviations or medians and interquartile range [25th
percentile, 75th percentile] for continuous data; frequencies and percentages for categorical
data) will be calculated by group.
Comparability of the three groups at baseline will be analyzed using the chi-square test or
Fisher's exact test, as deemed appropriate, for categorical variables. Continuous variables
such as age and narcotic usage will be compared using Analysis of Variance (ANOVA) or the
Kruskal-Wallis test as indicated.
For the primary outcome, the 24 hour VAS score will be compared between the liposomal
bupivacaine vs. bupivacaine groups using the two-sample t-test or Mann-Whitney test as deemed
appropriate.
A repeated measures analysis of variance (RMANOVA) with a mixed models approach will be used
to determine if the groups' trajectories for VAS differ across time, measured at 6, 12, 24,
and 48 hours post-operatively (i.e., the group x time interaction). The standard assumptions
of Gaussian residuals and equality of variance will be tested. If the normality assumption is
not met, a transformation will be used for the analysis of VAS. The repeated within subjects
factor will be time and the within subjects factor will be group (Saline, Liposomal
bupivicaine, or Bupivacaine).
"Time-to-first rescue pain medication after surgery" will be analyzed by applying standard
methods of survival analysis, i.e., computing the Kaplan-Meier product limit curves, where
group will be the stratification variable. In cases where the endpoint event, "first rescue
pain medication after surgery", did not occur, the number of hours until last follow-up will
be used and considered 'censored'. The groups will be compared using the log-rank test. The
median "time to first rescue pain medication after surgery" and corresponding 95% confidence
intervals for each group will be obtained from the Kaplan-Meier/Product-Limit Estimates.
LOS will also be analyzed using the standard methods of survival described above, however,
without any censored data.
A result will be considered statistically significant at the p<0.05 level of significance.
Upon finding a significant difference among the three groups in any of the above analyses,
Bonferroni adjusted multiple pairwise comparisons will be carried out in order to determine
specifically which groups differed from one another. A pairwise comparison will be considered
statistically significant if p<0.0167 (=0.05/3).
All analyses will be performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).
Intention-to-Treat (ITT):
Statistical analysis will be performed using the modified intention-to-treat population
(mITT), defined as all randomized subjects who receive treatment and who have completed at
least one pain score after baseline assessment.
Interim Analysis and Early Stopping:
There are no plans for interim analysis for efficacy.
Sample Size Considerations:
The proposed sample size for this prospective, single-blinded randomized trial is 99 subjects
(n=33 per group). The sample size is based on the primary analysis of VAS at 24 weeks between
the Liposomal bupivicaine vs. bupivicaine groups. Although other analyses will be performed
on all 3 groups, the sample size calculation has been simplified to the analysis of Liposomal
bupivicaine vs. bupivicaine at a single time point.
Based on data published by Kirac et al. (2013), the mean 24-hour VAS score for the
bupivicaine group was 2.8 ± 0.9. We assume that the VAS score at 24-hours for the Liposomal
bupivicaine group will be 25% greater (VAS=3.5). A sample size of 33 in each group will have
80% power to detect such a difference in means of -0.7 assuming that the common standard
deviation is 1.0 using a two group t-test with a 0.05 two-sided significance level. Expanding
this to 3 groups will yield a total sample size of 99 subjects.
Outcomes The primary outcome being assessed is the patient's pain rating at 24 hours after
the procedure. All patient scores will be recorded using a specific VAS, the Wong-Baker FACES
Pain Rating Scale. These values will be converted to a numerical scale from 0-10 accordingly.
Patients will be assigned a pain rating handout which will be present in their hospital room
for 48 hours or until they are discharged, whichever comes first. Nursing staff or a urology
inpatient team member will prompt the patient at the 24 hour period to describe their pain
using the FACES scale and they will record this on their handout. Nursing or a urology
inpatient team member will collect handouts at time of discharge or after 48 hours, whichever
comes first.
The following data will also be recorded and serve as the secondary outcomes:
1. Patient's pain rating at 6, 12, and 48 hours in all arms
2. Patient's pain rating at 24 hours in the saline arm
3. Patient length of stay (LOS)
4. Time-to-first rescue pain medication after surgery
5. Total narcotic use
6. Weight adjusted total narcotics use
7. Narcotic density (mg of morphine equivalent/hours) used at 0-6 hours, 6-12 hours, 12-24
hours, 24-48 hours
Additionally, patient demographics and clinical characteristics such as age, gender, BMI, and
previous medical and surgical history will be collected. Procedural characteristics such as
location of tracts (supracostal vs infracostal), size of nephrostomy tract, and type of
nephrostomy tube will be recorded.
A secondary outcome that deserves further mention will be the total dose of narcotics from
over the inpatient hospital course. This will be measured from 1 hour after the patient
reaches the post-anesthesia care unit (PACU) until the discharge order is placed. All opiate
medication will be converted morphine equivalents and the values will be reported as total
number of milligrams of morphine. In order to help reduce variability due to variations in
prescriber patterns, patients will be started on a pain regimen as followed.
Mild pain: 1 tablet PO Oxycodone 5mg/Acetaminophen 325mg q4 hours Moderate pain: 2 tablets PO
Oxycodone 5mg/Acetaminophen 325mg q4 hours Severe pain: 1 mg IV hydromorphone q4 hours
Breakthrough pain: 0.5 mg IV hydromorphone q4 hours The analgesic regimen can be altered by
the physician or physician assistant treating the patient at their discretion but efforts
will be maintained to follow this analgesic regimen. Amount of narcotics used will be gleaned
from the electronic medical record upon discharge of the patient. Time to start recording
analgesics will begin one hour after patient is sent to the PACU. This will help decrease
variability in anesthesiologist and peri-anesthesia prescribing patterns immediately at the
conclusion of the procedure.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT03181620 -
Sedation Administration Timing: Intermittent Dosing Reduces Time to Extubation
|
N/A | |
Completed |
NCT04579354 -
Virtual Reality (VR) Tour to Reduce Preoperative Anxiety Before Anaesthesia
|
N/A | |
Recruiting |
NCT06007378 -
Optimizing Postoperative Pain Control After Laparoscopic Colorectal Surgery
|
N/A | |
Recruiting |
NCT05943015 -
Analgesic Efficacy of Quadratus Lumborum, Paravertebral Blocks
|
N/A | |
Completed |
NCT04544228 -
Ketamine or Neostigmine for Serratus Anterior Plane Block in Modified Radical Mastectomy
|
N/A | |
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Completed |
NCT03663478 -
Continuous TQL Block for Elective Cesarean Section
|
Phase 4 | |
Completed |
NCT04176822 -
Designing Animated Movie for Preoperative Period
|
N/A | |
Completed |
NCT05170477 -
Influence of Apical Patency Concept Upon Postoperative Pain After Root Canal Treatment
|
N/A | |
Completed |
NCT06425601 -
A Comparison of Silicone Versus Polyvinylchloride (PVC) Drains Following VATS Lobectomy
|
N/A | |
Not yet recruiting |
NCT04561856 -
Fascia Iliaca Block Supplemented With Perineural Vs Intravenous Dexamethasone
|
Phase 4 | |
Completed |
NCT03612947 -
TAP Block in Laparoscopic Cholecystectomy.
|
Phase 2 | |
Completed |
NCT05974501 -
Pre vs Post Block in Total Knee Arthroplasty (TKA)
|
Phase 4 | |
Completed |
NCT05995912 -
Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain
|
Phase 2 | |
Completed |
NCT04571515 -
Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain
|
Phase 2 | |
Active, not recruiting |
NCT04190355 -
The Effect of Irrigant Types Used During Endodontic Treatment on Postoperative Pain
|
N/A | |
Recruiting |
NCT05145153 -
Incidence of Chronic Pain After Thoracic Surgery
|
||
Recruiting |
NCT03697278 -
Monitoring Postoperative Patient-controlled Analgesia (PCA)
|
N/A |